Why the study?
The molecular pathogenesis of cardiomyopathy remains unclear and treatment options are limited to palliative therapy, making the identification of novel therapeutic targets crucial.
Design
Review
Authors
Loading...
Extends evidence linking PANoptosis to cardiomyopathy; leaves open whether targeting it improves outcomes.
PANoptosis, an integrated cell death process, is emerging as a key mediator and potential therapeutic target for the treatment of cardiomyopathy.
Sun et al. (2025) studied this question.